Ascendis Pharma A/S Ordinary Share (ASND)

FairStock Score: 32/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

At $223.21 on 2026-10-13, Ascendis Pharma has a $14.1 billion market value. In the latest reported quarter, fiscal Q2 2026, revenue was $339.3 million and net income was $207.0 million, a 61.00% margin. That is a remarkable turn toward profitability, and trailing free cash flow is $335.1 million. The balance sheet looks sound, with debt-to-equity of 0.31 and an Altman Z-Score of 9.79, while Piotroski is 6/9. The business sells approved rare-disease endocrinology therapies, which can carry pricing power and regulatory barriers, but a true moat requires durable reimbursement and pipeline execution, not one good quarter. FairStock's calculations at the 2026-10-13 close show P/E 17.40, which looks undemanding if profits persist, but P/B is 8.89, EV/EBITDA is 58.13, FCF yield is only 2.4%, and the Graham Number is $79.46. That implies a margin of safety of -180.91%. FairStock's score is 32/100, and the Lynch category is none because only 0 years of filed results exist, not the three needed. ROE is 118.78%, but ROCE is just 9.58%, showing that reported returns may be flattered by a small equity base. I see a promising commercial-stage biotech with recent momentum, but the price already reflects a lot. Graham would demand a wider cushion; Buffett would want proof the economics are durable.

In plain English: Ascendis Pharma makes medicines for rare diseases, including growth-hormone deficiency and chronic hypoparathyroidism. The latest reported quarter, fiscal Q2 2026, showed $339.3 million of revenue and $207.0 million of net income, and the company has little debt. But it has only a short record as a profitable company, and at the 2026-10-13 close of $223.21 the price looks high compared with the value suggested by its profits and assets.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer